Table 1.
Baseline sociodemographic and clinical characteristics, by treatment
| Characteristic | Olanzapine-LAI | Olanzapine | Pa |
|---|---|---|---|
| Number of patients | (n=264) | (n=260) | |
| Female, n (%) | 89 (33.7) | 83 (31.9) | 0.66 |
| Age at study entry (years), mean (SD) | 41.7 (10.9) | 40.1 (10.8) | 0.09 |
| Age at onset (years), mean (SD) | 25.9 (9.2) | 26.5 (8.7) | 0.28 |
| CGI-S score, mean (SD) | 3.2 (0.8) | 3.3 (0.7) | 0.82 |
| PANSS total score, mean (SD) | 56.7 (9.8) | 56.6 (8.7) | 0.43 |
| In paid employment, n (%) | 56 (21.3) | 48 (18.5) | 0.43 |
| Living independently, n (%) | 67 (25.5) | 56 (21.6) | 0.29 |
Note:
a
P-value comparing olanzapine-LAI with oral olanzapine.
Abbreviations: LAI, long-acting injection; SD, standard deviation; CGI-S, Clinical Global Impression–Severity; PANSS, Positive and Negative Symptom Scale.